<DOC>
	<DOCNO>NCT01702558</DOCNO>
	<brief_summary>This multicenter study assess maximum tolerate dose capecitabine combination Kadcyla ( trastuzumab emtansine ) participants HER2-positive mBC HER2-positive LA/mGC use Phase I design , follow randomize , open-label Phase II study explore efficacy safety combination Kadcyla capecitabine compare Kadcyla alone mBC . The anticipated time study treatment disease progression , intolerable toxicity , withdrawal consent .</brief_summary>
	<brief_title>A Combination Study Kadcyla ( Trastuzumab Emtansine ) Capecitabine Participants With Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Metastatic Breast Cancer ( mBC ) HER2-Positive Locally Advanced/Metastatic Gastric Cancer ( LA/mGC )</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Metastatic Breast Cancer Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Adequate blood cell count Adequate liver , renal , cardiac function Life expectancy great equal ( &gt; /= ) 12 week Histologically cytologically confirm breast cancer Confirmed HER2positive disease , define immunohistochemistry ( IHC ) 3+ situ hybridization ( ISH ) positive mBC least one measurable lesion accord RECIST version 1.1 Disease progression least one prior regimen contain trastuzumab chemotherapy either separately combination ; participant may eligible receive study therapy firstline set trastuzumab chemotherapy give neoadjuvant/adjuvant setting Recovered previous treatment Locally Advanced/Metastatic Gastric Cancer ECOG performance status 0 , 1 , 2 Adequate blood cell count Adequate liver , renal , cardiac function Life expectancy &gt; /= 12 week Histologically cytologically confirm LA/mGC HER2positive tumor ( primary tumor metastatic lesion ) , define either IHC 3+ IHC 2+ ISHpositive Inoperable LA/mGC Metastatic Breast Cancer Prior treatment first study treatment : 1 . Investigational therapy within 28 day 5 halflives , whichever long 2 . Hormonal therapy within 14 day 3 . Trastuzumab within 21 day Prior treatment trastuzumab emtansine prior enrollment trastuzumab emtansinecontaining study , regardless whether patient receive trastuzumab emtansine Prior treatment capecitabine History severe unexpected reaction fluoropyrimidine know hypersensitivity fluorouracil Related capecitabine contraindication 1 . Treatment sorivudine chemicallyrelated analogue 2 . Rare hereditary problem galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption 3 . Complete absence dihydropyrimidine dehydrogenase ( DPD ) activity History intolerance hypersensitivity trastuzumab murine protein product component History exposure high cumulative dos anthracyclines Brain metastasis symptomatic require radiation , surgery , steroid therapy control symptom within 28 day study drug Current peripheral neuropathy Grade &gt; /=3 History malignancy within last 5 year , except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage I uterine cancer , cancer similar outcome Current unstable ventricular arrhythmia require treatment History symptomatic congestive heart failure ( CHF ) History myocardial infarction unstable angina within 6 month prior study drug History leave ventricular ejection fraction ( LVEF ) less ( &lt; ) 40 % symptomatic CHF previous trastuzumab treatment Severe dyspnea rest due complication advance malignancy currently require continuous oxygen therapy Clinically significant malabsorption syndrome inability take oral medication Current severe , uncontrolled systemic disease ( clinically significant cardiovascular , pulmonary , metabolic disease ) Major surgical procedure significant traumatic injury within 28 day enrollment anticipation need major surgery study treatment Current know active infection human immunodeficiency virus ( HIV ) hepatitis B C Lapatinib within 14 day study drug Locally Advanced/Metastatic Gastric Cancer Same , addition previous chemotherapy advanced/metastatic disease ( prior adjuvant/neoadjuvant therapy allow least 6 month elapse completion adjuvant/neoadjuvant therapy enrollment study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>